CoChat
Sign Up
Cited by 143Cancer-related Molecular PathwaysBRCA gene mutations in cancerOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 136 of the 172 references it cites were found in a registry or an index.

Mutational spectrum of p53 mutations in primary breast and ovarian tumors

Feki, Anis, Irminger-Finger, Irmgard·2004·Critical Reviews in Oncology/Hematology
DOI 10.1016/j.critrevonc.2004.07.002
Open this paper in CoChat — free account

Abstract

Breast and ovarian cancers, like other cancers, occur due to genetic damage. Research aimed to determine the specific genes involved in the development of breast and ovarian cancers will help to understand how normal breast and ovarian epithelial cells escape regulation of proliferation, apoptosis and senescence. It was determined that approximately 10% of ovarian cancers and 20-30% of breast cancers arise in women who have inherited mutations in cancer susceptibility genes such as BRCA1, BRCA2 and other DNA repair genes. The ability to perform genetic testing permits the identification of women at increased risk who can then be offered preventive strategies. The vast majority of ovarian and breast cancers are sporadic, presumably resulting from the accumulation of genetic damage over lifetime. Several genes involved in breast and ovarian carcinogenesis have been identified, most notably the p53 tumor suppressor. The recent availability of expression microarrays has facilitated the simultaneous screening of thousands of genes and this will extend further the understanding of molecular events involved in the dynamic development of ovarian and breast cancers. Then, all this knowledge could be translated into effective screening, surveillance, prevention, and treatment strategies in the future.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.critrevonc.2004.07.002

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 172 references

Research works printed but not linked: 2

  1. Takahashi, 2000, Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers, Int J Cancer, 89, 92, 10.1002/(SICI)1097-0215(20000120)89:1<92::AID-IJC15>3.0.CO;2-8 · DOI
  2. HK. Annual report on the results of treatment in gynecological cancer. Vol. 18. Stokholm: FIGO; 1982.

Cited by

Sorted by citations

Items 101–143 of 143

Related

See all

Metadata

Authors
Feki, A., & Irminger-Finger, I.
Venue
Critical Reviews in Oncology/Hematology
Publisher
Elsevier BV
Published
2004-11
Volume
52
Issue
2
Pages
103-116
ISSN
1040-8428 (ISSN-L)
DOI
10.1016/j.critrevonc.2004.07.002
OpenAlex
W2071475683
Cited by
139
References
172
Citations by year
2025: 5 · 2024: 3 · 2023: 3 · 2022: 5 · 2021: 7 · 2020: 5 · 2019: 4 · 2018: 4 · 2017: 9 · 2016: 4 · 2015: 13 · 2014: 7 · 2013: 12 · 2012: 9
FWCI
0.57
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Critical Reviews in Oncology/Hematology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords
TP53 mutation, mutation spectrum, breast cancer, ovarian cancer, tumor suppressor, BRCA1, BRCA2, hereditary cancer predisposition, sporadic cancer, carcinogenesis, DNA repair genes, genetic testing, cancer prevention
MeSH terms
Breast Neoplasms, Family Health, Female, Gene Frequency, Humans, Mutation, Ovarian Neoplasms, Prognosis, Tumor Suppressor Protein p53

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review